WAT — Waters Corporation

Waters Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $1.267 billion, comprising $747 million in organic revenue and $520 million from newly acquired Biosciences and Diagnostic Solutions.
• Organic Revenue Growth: 13% as reported, 11% in constant currency, exceeding guidance by 200 basis points.
• Adjusted EPS: Grew 20% year-over-year to $2.70, surpassing guidance by $0.35.
• Adjusted Gross Margin: 54.7%, approximately 200 basis points better than expected.
• Adjusted Operating Margin: 23.6%, also about 200 basis points better than expected.
• Free Cash Flow: $42 million outflow due to transaction costs and cash settlement timing.

2. Strategic Updates and Business Highlights:

• The company is experiencing strong momentum across its four divisions, with double-digit organic growth in legacy businesses and better-than-expected performance from acquired businesses.
• The Analytical Sciences division reported a 12% growth in constant currency, driven by strong instrument replacement and new product adoption.
• The Advanced Diagnostics division showed growth despite challenges in China, with microbiology revenue increasing by 10%.
• The company launched a 180-day growth revitalization plan post-acquisition, focusing on operational improvements, pricing discipline, and increased customer engagement.
• New product launches include the BACTEC FXI blood culture system and next-generation Microflow LC Chemistry Columns.

3. Forward Guidance and Outlook:

• 2026 Organic Revenue Growth Guidance: Raised to 6.5% to 8%, reflecting strong Q1 performance and embedding $15 million in expected revenue synergies.
• Total 2026 Revenue Expectation: Approximately $6.405 billion to $6.455 billion.
• Adjusted EPS Guidance for 2026: Increased by $0.10 to a range of $14.40 to $14.60, indicating a growth of 10% to 11%.
• Q2 2026 Guidance: Organic constant currency revenue growth of 6% to 8%, with total reported revenue expected between $1.616 billion and $1.631 billion.

4. Bad News, Challenges, or Points of Concern:

• Headwinds in Respiratory Testing: A $20 million impact due to a weak flu season.
• China-Related Constraints: Ongoing export restrictions and a lack of localized product portfolio continue to pressure growth in the Biosciences division.
• Market Competition: The company faces competition from private equity-owned businesses, particularly in microbiology and flow cytometry, which could impact pricing and market share.
• Pro Forma Growth Decline: The Biosciences division experienced a 1% decline on a full quarter pro forma basis, although this was an improvement from previous quarters.

5. Notable Q&A Insights:

• Management highlighted the importance of the 180-day plan in revitalizing growth and improving operational execution, with early signs of success already visible.
• There was a discussion on the differences in competition from private equity firms, with management expressing confidence in maintaining pricing discipline and leveraging innovation.
• The conversation around the LCMS instrument replacement cycle indicated a strong current momentum, with potential for continued growth into 2027, although there may be a future air pocket in 2028.
• Management emphasized the strong demand in the biopharma sector, particularly in China, which is driving growth and providing a favorable backdrop for future performance.

Overall, Waters Corporation reported a strong start to 2026, with positive growth metrics and strategic initiatives in place to drive future performance, despite facing some market challenges and headwinds.